Dr. Eddie Garon presents data from CANOPY-A - adjuvant canakinumab for resected NSCLC #ESMO22
Canakinumab in the CANTOS study was associated with a reduction in NSCLC incidence. Led to CANOPY-A: large study of adjuvant canakinumab after surgery and chemotherapy for NSCLC. #ESMO22
Adjuvant canakinumab did not improve DFS (HR 0.939). CANOPY-A clearly a negative study. #ESMO22
No clear signals in the subgroup analysis. Survival shown here (exploratory) and fewer events overall than expected. Lung cancer specific mortality similar between both arms. Rates of AEs also similar between two arms. #ESMO22
Other canakinumab studies pending full analysis and biomarker data to come but disappointing results overall. Did the CANTOS data support exploration in these very different clinical settings? #ESMO22
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.